Philochem and Blue Earth Diagnostics celebrate a pivotal advancement in their collaboration, initiating a Phase 1 Clinical Trial with 68Ga-OncoFAP for imaging solid tumors. This partnership aims to explore OncoFAP, a specialized ligand targeting Fibroblast Activation Protein (FAP), displaying promising outcomes in preclinical models and human subjects. Imaging the first three patients at the National Cancer Institute of Milan underscores a significant milestone. The remarkable potential of OncoFAP technology hints at a transformative shift in tumor diagnosis, offering renewed hope for improved patient care and innovative treatment strategies.
Philochem AG and Blue Earth Diagnostics join forces in a groundbreaking Phase 1 Clinical Trial, introducing 68Ga-OncoFAP for imaging solid tumors. This strategic collaboration focuses on harnessing OncoFAP, a novel Fibroblast Activation Protein (FAP)-targeting ligand, with promising preclinical and human study results. The recent imaging of the initial three patients at the National Cancer Institute of Milan represents a critical milestone in advancing diagnostic approaches. OncoFAP technology’s potential breakthrough underscores the prospect of redefining tumor diagnosis and signifies a pivotal step toward elevating patient care standards.
Philochem and Blue Earth Diagnostics revealed insights into their March 2022 collaboration on OncoFAP’s development for diagnosing solid tumors. The agreement involves evaluating the safety and dosimetry of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) in a Phase 1 clinical study for solid tumor imaging. FAP, found in 90% of epithelial cancers, led to the first imaging of three patients in November 2023 at Milan’s National Cancer Institute. Philochem and the University of Münster, Germany, have previously used 68Ga-OncoFAP-DOTAGA in approximately 100 solid tumor patients. This innovative technology shows promise for enhancing tumor diagnosis and patient care.
Dr. Dario Neri, Philochem Board Member and CEO of Philogen Group expressed enthusiasm for the performance of 68Ga-OncoFAP, citing its potential for revolutionizing tumor diagnosis. David Gauden, CEO of Blue Earth Diagnostics, hailed the dosing of the first three patients in the Phase 1 trial as a significant milestone. 68Ga-OncoFAP presents a promising addition to Blue Earth Diagnostics’ PET radiopharmaceuticals portfolio, with impressive properties observed in preclinical and early clinical phases.
Fibroblast Activation Protein (FAP), abundant in cancer-associated fibroblasts, holds diagnostic and therapeutic promise in numerous cancers. Using radiolabeled ligands like 68Ga or 18F, FAP-targeted technology showcases high affinity and rapid tumor binding, facilitating precise PET imaging. This technology may revolutionize diagnostic imaging and therapy in various cancers and fibrotic conditions.
Philochem and Blue Earth Diagnostics pave the way for innovation, achieving a significant milestone by imaging the first three patients in their Phase 1 Clinical Trial featuring 68Ga-OncoFAP for solid tumor imaging. This collaborative effort underscores the promise of OncoFAP, a specialized ligand targeting Fibroblast Activation Protein (FAP), offering potential breakthroughs in tumor diagnosis. The robust preclinical and human study outcomes herald a transformative era in diagnostic imaging, suggesting a paradigm shift in patient care. As this pioneering initiative progresses, it holds the promise of shaping future standards in precision medicine and significantly impacting cancer diagnosis and treatment strategies.
